Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for … – Business Wire (press release)
Labiotech.eu |
Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR–T Therapy Candidate for …
Business Wire (press release) SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a … Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel review Kite Pharma (KITE) Q2 Loss Narrower than Expected, Sales Beat Kite Pharma, Inc. (KITE) Reached a New 52-Week High |
